Simulations Plus' (SLP) "Neutral" Rating Reaffirmed at BTIG Research

Key Points

• BTIG Research reaffirmed its “neutral” rating on Simulations Plus, while other analysts also largely maintained cautious views. The consensus rating is “Reduce,” with an average price target of $17.25.
• Simulations Plus reported quarterly adjusted earnings of $0.30 per share, exceeding the $0.23 consensus estimate, while revenue of $21.89 million also topped expectations.
• SLP shares opened at $18.50, giving the company a market capitalization of approximately $374.1 million. Institutional investors own about 78.08% of the outstanding stock.

Simulations Plus (NASDAQ:SLP - Get Free Report)'s stock had its "neutral" rating restated by stock analysts at BTIG Research in a research note issued on Wednesday, Benzinga reports.

SLP has been the topic of a number of other research reports. William Blair lowered Simulations Plus from an "outperform" rating to a "market perform" rating in a research report on Wednesday, June 17th. Wall Street Zen downgraded shares of Simulations Plus from a "buy" rating to a "hold" rating in a report on Saturday, June 13th. Craig Hallum lowered shares of Simulations Plus from a "buy" rating to a "hold" rating and set a $18.50 price objective on the stock. in a research report on Thursday, June 18th. Finally, Weiss Ratings upgraded shares of Simulations Plus from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, July 10th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $17.25.

Simulations Plus Stock Performance

Shares of SLP opened at $18.50 on Wednesday. The firm has a market cap of $374.06 million, a P/E ratio of 46.24 and a beta of 1.31. Simulations Plus has a twelve month low of $11.09 and a twelve month high of $21.01. The firm's 50 day moving average price is $18.40 and its two-hundred day moving average price is $16.61.

Simulations Plus (NASDAQ:SLP - Get Free Report) last issued its quarterly earnings data on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.07. The company had revenue of $21.89 million during the quarter, compared to the consensus estimate of $20.90 million. Simulations Plus had a net margin of 9.88% and a return on equity of 13.50%.

Hedge Funds Weigh In On Simulations Plus

A number of hedge funds have recently bought and sold shares of the business. First Light Asset Management LLC boosted its holdings in Simulations Plus by 6.1% in the 2nd quarter. First Light Asset Management LLC now owns 2,792,677 shares of the technology company's stock valued at $51,134,000 after purchasing an additional 159,854 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of Simulations Plus in the second quarter valued at approximately $26,000. Groupe la Francaise bought a new stake in shares of Simulations Plus in the second quarter valued at approximately $2,329,000. Susquehanna International Group LLP grew its position in Simulations Plus by 76.2% during the second quarter. Susquehanna International Group LLP now owns 29,965 shares of the technology company's stock worth $549,000 after buying an additional 12,959 shares in the last quarter. Finally, Hsbc Holdings PLC increased its stake in Simulations Plus by 6.1% during the 2nd quarter. Hsbc Holdings PLC now owns 28,116 shares of the technology company's stock worth $520,000 after acquiring an additional 1,622 shares during the period. 78.08% of the stock is owned by institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops software and provides services that support pharmaceutical research, drug development and regulatory decision-making. Its technologies help scientists model how drug compounds behave in the body, assess formulation and delivery characteristics, and evaluate potential safety and efficacy outcomes.

The company's software portfolio includes GastroPlus, a platform for physiologically based pharmacokinetic and pharmacodynamic modeling; ADMET Predictor, which forecasts absorption, distribution, metabolism, excretion and toxicity properties; and DDDPlus, which simulates drug dissolution and dosage-form performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.